Pacer Advisors Portfolio holdings
AUM
$39.6B
1-Year Return
5.04%
This Quarter Return
+9.61%
1 Year Return
+5.04%
3 Year Return
+42.86%
5 Year Return
+91.64%
10 Year Return
+332.32%
AUM
$43.5B
AUM Growth
+$8.16B
(+23%)
Cap. Flow
+$3.86B
Cap. Flow
% of AUM
8.88%
Top 10 Holdings %
Top 10 Hldgs %
11.55%
Holding
3,919
New
249
Increased
1,063
Reduced
1,013
Closed
119
Top Buys
| 1 |
Kenvue
KVUE
|
$439M |
| 2 |
AT&T
T
|
$437M |
| 3 |
Cummins
CMI
|
$427M |
| 4 |
Bunge Global
BG
|
$340M |
| 5 |
DaVita
DVA
|
$232M |
Top Sells
| 1 |
Qualcomm
QCOM
|
$453M |
| 2 |
AbbVie
ABBV
|
$447M |
| 3 |
Phillips 66
PSX
|
$441M |
| 4 |
D.R. Horton
DHI
|
$440M |
| 5 |
Booking.com
BKNG
|
$405M |
Sector Composition
| 1 | Consumer Discretionary | 17.42% |
| 2 | Energy | 16.95% |
| 3 | Industrials | 11.93% |
| 4 | Technology | 11.17% |
| 5 | Healthcare | 10.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SWI
1326
DELISTED
SolarWinds Corporation Common Stock
SWI
| $33.6K | ﹤0.01% |
2,664
+1,996
| +299% | +$25.2K |
|
1327
Tower Semiconductor
TSEM
$7.07B
| $33.4K | ﹤0.01% |
998
-36
| -3% | -$1.2K |
|
1328
Viridian Therapeutics
VRDN
$1.53B
| $33.3K | ﹤0.01% |
+1,900
| New | +$33.3K |
|
|
INBX
1329
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $32.9K | ﹤0.01% |
+942
| New | +$32.9K |
|
1330
ImmunityBio
IBRX
$2.27B
| $32.7K | ﹤0.01% |
+6,097
| New | +$32.7K |
|
1331
Protagonist Therapeutics
PTGX
$3.77B
| $32.2K | ﹤0.01% |
+1,113
| New | +$32.2K |
|
1332
C4 Therapeutics
CCCC
$194M
| $32.1K | ﹤0.01% |
+3,929
| New | +$32.1K |
|
1333
Veracyte
VCYT
$2.55B
| $31.8K | ﹤0.01% |
+1,437
| New | +$31.8K |
|
1334
JFrog
FROG
$5.84B
| $31.8K | ﹤0.01% |
720
-24
| -3% | -$1.06K |
|
1335
Global E Online
GLBE
$6.07B
| $31.5K | ﹤0.01% |
866
-32
| -4% | -$1.16K |
|
1336
Mirum Pharmaceuticals
MIRM
$3.82B
| $31.1K | ﹤0.01% |
+1,240
| New | +$31.1K |
|
1337
Kura Oncology
KURA
$713M
| $31K | ﹤0.01% |
+1,451
| New | +$31K |
|
1338
NetEase
NTES
$85B
| $30.7K | ﹤0.01% |
297
+117
| +65% | +$12.1K |
|
1339
Agios Pharmaceuticals
AGIO
$2.09B
| $30.1K | ﹤0.01% |
+1,031
| New | +$30.1K |
|
1340
Arcus Biosciences
RCUS
$1.3B
| $29.8K | ﹤0.01% |
+1,579
| New | +$29.8K |
|
1341
Disc Medicine
IRON
$2.11B
| $29.7K | ﹤0.01% |
+477
| New | +$29.7K |
|
1342
Scholar Rock
SRRK
$3.02B
| $28.6K | ﹤0.01% |
+1,612
| New | +$28.6K |
|
1343
Corcept Therapeutics
CORT
$7.31B
| $28.3K | ﹤0.01% |
1,124
-173
| -13% | -$4.36K |
|
1344
Semtech
SMTC
$5.26B
| $28.3K | ﹤0.01% |
1,028
+781
| +316% | +$21.5K |
|
1345
Mesa Laboratories
MLAB
$356M
| $28.2K | ﹤0.01% |
257
+135
| +111% | +$14.8K |
|
1346
Cabaletta Bio
CABA
$155M
| $28.2K | ﹤0.01% |
+1,653
| New | +$28.2K |
|
1347
Editas Medicine
EDIT
$248M
| $27.8K | ﹤0.01% |
+3,748
| New | +$27.8K |
|
1348
3D Systems Corporation
DDD
$272M
| $27.8K | ﹤0.01% |
6,262
| – | – |
|
|
VERV
1349
DELISTED
Verve Therapeutics
VERV
| $26.7K | ﹤0.01% |
+2,013
| New | +$26.7K |
|
1350
Gogo Inc
GOGO
$1.43B
| $26.3K | ﹤0.01% |
2,992
+1,737
| +138% | +$15.3K |
|